HMPL 506
Alternative Names: HMPL-506Latest Information Update: 12 Jun 2024
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Small molecules
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies
Most Recent Events
- 06 Jun 2024 Phase-I clinical trials in Leukaemia (Second-line therapy or greater) in China (PO) (NCT06387082)
- 05 Apr 2024 Adverse event data from a preclinical trial in Leukemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 HUTCHMED plans a phase I trial for HMPL 506 in second half of 2024